- Home
- SYRE vs TRIN Comparison
SYRE vs TRIN Comparison
Compare SYRE & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- TRIN
- Stock Information
- Founded
- SYRE 2013
- TRIN 2007
- Country
- SYRE United States
- TRIN United States
- Employees
- SYRE N/A
- TRIN N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- TRIN Finance/Investors Services
- Sector
- SYRE Health Care
- TRIN Finance
- Exchange
- SYRE Nasdaq
- TRIN Nasdaq
- Market Cap
- SYRE 1.1B
- TRIN 1.2B
- IPO Year
- SYRE 2016
- TRIN 2021
- Fundamental
- Price
- SYRE $16.23
- TRIN $14.74
- Analyst Decision
- SYRE Strong Buy
- TRIN Buy
- Analyst Count
- SYRE 6
- TRIN 4
- Target Price
- SYRE $57.60
- TRIN $15.75
- AVG Volume (30 Days)
- SYRE 681.2K
- TRIN 1.0M
- Earning Date
- SYRE 11-06-2025
- TRIN 11-05-2025
- Dividend Yield
- SYRE N/A
- TRIN 13.84%
- EPS Growth
- SYRE N/A
- TRIN 32.58
- EPS
- SYRE N/A
- TRIN 2.25
- Revenue
- SYRE N/A
- TRIN $254,887,000.00
- Revenue This Year
- SYRE N/A
- TRIN $27.19
- Revenue Next Year
- SYRE N/A
- TRIN $8.97
- P/E Ratio
- SYRE N/A
- TRIN $6.56
- Revenue Growth
- SYRE N/A
- TRIN 33.44
- 52 Week Low
- SYRE $10.91
- TRIN $12.50
- 52 Week High
- SYRE $40.26
- TRIN $16.82
- Technical
- Relative Strength Index (RSI)
- SYRE 52.04
- TRIN 29.74
- Support Level
- SYRE $15.87
- TRIN $15.05
- Resistance Level
- SYRE $17.18
- TRIN $15.63
- Average True Range (ATR)
- SYRE 0.88
- TRIN 0.36
- MACD
- SYRE 0.08
- TRIN -0.16
- Stochastic Oscillator
- SYRE 70.65
- TRIN 4.24
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.